# EDGAR Filing Document

**Accession Number:** 0001703647
**File Stem:** 0001193125-26-024394
**Filing Date:** 2026-1
**Character Count:** 17433
**Document Hash:** 5dd95e234b3997957f2f051572e904b7
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-26-024394.hdr.sgml**: 20260127

**ACCESSION NUMBER**: 0001193125-26-024394

**CONFORMED SUBMISSION TYPE**: S-8

**PUBLIC DOCUMENT COUNT**: 14

**FILED AS OF DATE**: 20260127

**DATE AS OF CHANGE**: 20260127

**EFFECTIVENESS DATE**: 20260127

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Korro Bio, Inc.
- **CENTRAL INDEX KEY:** 0001703647
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 472324450
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** S-8
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-292984
- **FILM NUMBER:** 26565438

**BUSINESS ADDRESS:**
- **STREET 1:** 60 FIRST STREET
- **STREET 2:** 2ND FLOOR, SUITE 250
- **CITY:** CAMBRIDGE
- **STATE:** MA
- **ZIP:** 02141
- **BUSINESS PHONE:** 617-468-1999

**MAIL ADDRESS:**
- **STREET 1:** 60 FIRST STREET
- **STREET 2:** 2ND FLOOR, SUITE 250
- **CITY:** CAMBRIDGE
- **STATE:** MA
- **ZIP:** 02141

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Frequency Therapeutics, Inc.
- **DATE OF NAME CHANGE:** 20170412

**As filed with the Securities and Exchange Commission on January 27, 2026** 

**Registration No. 333-**

**UNITED STATES** 

**SECURITIES AND EXCHANGE COMMISSION** 

**Washington, D.C. 20549** 

**FORM S-8**

**REGISTRATION STATEMENT** 

***UNDER*** 

***THE SECURITIES ACT OF 1933*** 

------

**KORRO BIO, INC.** 

**(Exact name of registrant as specified in its charter)** 

------

---

| | |
|:---|:---|
| **Delaware** | **47-2324450** |
| **(State or other jurisdiction of**<br>**incorporation or organization)** | **(I.R.S. Employer**<br>**Identification No.)** |

---

**60 First Street, 2nd floor, Suite 250** 

**Cambridge, Massachusetts 02141** 

(Address of Principal Executive Offices, Zip Code)

**Korro Bio, Inc. 2023 Stock Option and Incentive Plan** 

**Korro Bio, Inc. 2023 Employee Stock Purchase Plan** 

(Full title of the plan)

**Ram Aiyar** 

**President and Chief Executive Officer** 

**Korro Bio, Inc.** 

**60 First Street, 2nd floor, Suite 250**

**Cambridge, Massachusetts 02141** 

(Name and address of agent for service)

**(617) 468-1999**

(Telephone number, including area code, of agent for service)

------

***Copies to:*** 

---

| | |
|:---|:---|
| **Jeffrey Cerio, Esq.**<br>**General Counsel**<br>**Korro Bio, Inc.**<br>**60 First Street, 2nd floor, Suite 250**<br>**Cambridge, Massachusetts 02141**<br>**(617) 468-1999** | **Kingsley L. Taft, Esq.** <br>**Marianne C. Sarrazin, Esq.** <br>**Goodwin Procter LLP** <br>**100 Northern Avenue** <br>**Boston, MA 02210** <br>**(617) 570-1000** |

---

------

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

---

| | | | |
|:---|:---|:---|:---|
| Large accelerated filer | ☐ | Accelerated filer | ☐ |
| Non-accelerated filer | ☒ | Smaller reporting company | ☒ |
|  |  | Emerging growth company | ☐ |

---

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.

------

**EXPLANATORY NOTE** 

Korro Bio, Inc. is filing this Registration Statement on Form S-8 for the purpose of registering an additional 470,865 shares of its common stock, par value $0.001 per share (the "Common Stock"), under the Korro Bio, Inc. 2023 Stock Option and Incentive Plan (the "2023 Plan") and an additional 83,231 shares of Common Stock under the Korro Bio, Inc. 2023 Employee Stock Purchase Plan (the "2023 ESPP"), pursuant to the provisions of each plan that provide for annual automatic increases in the number of shares of Common Stock reserved for issuance under each plan. In each case, the additional shares are of the same class as other securities for which a registration statement relating to the 2023 Plan and the 2023 ESPP has previously been filed and is effective. Accordingly, this registration statement incorporates by reference the contents of the registration statement on Form S-8 ([<u>File No. 333-275354</u>](https://www.sec.gov/Archives/edgar/data/1703647/000119312523271472/d574866ds8.htm)), filed with the Securities and Exchange Commission (the "Commission") on November 6, 2023, the registration statement on Form S-8 ([<u>File No. 333-278245</u>](https://www.sec.gov/Archives/edgar/data/1703647/000119312524077693/d814264ds8.htm)), filed with the Commission on March 26, 2024, and the registration statement on Form S-8 ([<u>File No. 333-285873</u>](https://www.sec.gov/Archives/edgar/data/1703647/000095017025040760/krro-20250318.htm)), filed with the Commission on March 18, 2025, relating to the 2023 Plan and the 2023 ESPP pursuant to General Instruction E, except with respect to Item 8. Exhibits thereof.

------

**Part II** 

**INFORMATION REQUIRED IN THE REGISTRATION STATEMENT**

---

| | |
|:---|:---|
| **Item 8.** | **Exhibits.**  |

---

**EXHIBIT INDEX** 

---

| | |
|:---|:---|
| **Exhibit<br>No.** | **Description** |

---

---

| | |
|:---|:---|
| 4.1 | [<u>Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.1 to the registrant's Current Report on Form 8-K filed on October 17, 2019).</u>](https://www.sec.gov/Archives/edgar/data/1703647/000119312519263787/d796545dex31.htm) |
| 4.2 | [<u>Certificate of Amendment to the Restated Certificate of Incorporation, dated November 3, 2023 (incorporated by reference to Exhibit 3.1 to the registrant's Current Report on Form 8-K filed on November 6, 2023).</u>](https://www.sec.gov/Archives/edgar/data/1703647/000119312523270898/d549338dex31.htm) |
| 4.3 | [<u>Certificate of Amendment to the Restated Certificate of Incorporation, dated November 3, 2023 (incorporated by reference to Exhibit 3.2 to the registrant's Current Report on Form 8-K filed on November 6, 2023).</u>](https://www.sec.gov/Archives/edgar/data/1703647/000119312523270898/d549338dex32.htm) |
| 4.4 | [<u>Certificate of Amendment to the Restated Certificate of Incorporation, dated June 11, 2024 (incorporated by reference to Exhibit 3.1 to the registrant's Current Report on Form 8-K filed on June 12, 2024).</u>](https://www.sec.gov/Archives/edgar/data/1703647/000119312524159933/d844802dex31.htm) |
| 4.5 | [<u>Amended and Restated Bylaws (incorporated by reference to Exhibit 3.1 to the registrant's Current Report on Form 8-K filed on September 23, 2020).</u>](https://www.sec.gov/Archives/edgar/data/1703647/000119312520253994/d62983dex31.htm) |
| 5.1\* | [<u>Opinion of Goodwin Procter LLP.</u>](krro-ex5_1.htm) |
| 23.1\* | [<u>Consent of Ernst & Young LLP.</u>](krro-ex23_1.htm) |
| 23.2\* | [<u>Consent of Goodwin Procter LLP (included in Exhibit 5.1).</u>](krro-ex5_1.htm) |
| 24.1\* | [<u>Power of Attorney (included on signature page).</u>](#poa) |
| 99.1 | [<u>Korro Bio, Inc. 2023 Stock Option and Incentive Plan, and forms of award agreements thereunder (incorporated by reference to Exhibit 10.1 to the registrant's Registration Statement on Form S-1/A filed on December 20, 2023).</u>](https://www.sec.gov/Archives/edgar/data/1703647/000119312523299978/d597314dex101.htm) |
| 99.2 | [<u>Korro Bio, Inc. 2023 Employee Stock Purchase Plan (incorporated by reference to Exhibit 10.2 to the registrant's Registration Statement on Form S-1/A filed on December 20, 2023).</u>](https://www.sec.gov/Archives/edgar/data/1703647/000119312523287451/d597314dex102.htm) |
| 107\* | [<u>Filing Fee table.</u>](krro_exfilingfees.htm) |

---

------

\* <u>Filed herewith.</u> 

------

**SIGNATURES** 

Pursuant to the requirements of the Securities Act, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Cambridge, Commonwealth of Massachusetts, on this 27th day of January, 2026.

---

| | |
|:---|:---|
| **KORRO BIO, INC.** | **KORRO BIO, INC.** |
| By: | /s/ Ram Aiyar |
|  | Name: Ram Aiyar<br>Title: President, Chief Executive Officer, Interim Chief Financial Officer and Director |

---

------

**POWER OF ATTORNEY AND SIGNATURES** 

KNOW ALL PERSONS BY THESE PRESENTS, that each individual whose signature appears below hereby constitutes and appoints each of Ram Aiyar, Jeffery Cerio and Oliver Dolan, as such person's true and lawful attorney-in-fact and agent with full power of substitution and resubstitution, for such person in such person's name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement, and to file the same, with all exhibits thereto, and all documents in connection therewith, with the Commission granting unto each said attorney-in-fact and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as such person might or could do in person, hereby ratifying and confirming all that any said attorney-in-fact and agent, or any substitute or substitutes of any of them, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act, this Registration Statement has been signed by the following person in the capacities and on the date indicated.

---

| | | |
|:---|:---|:---|
| **NAME** | **TITLE** | **DATE** |
| /s/ Ram Aiyar<br>Ram Aiyar | President, Chief Executive Officer, Interim Chief Financial Officer and Director<br>*Principal Executive Officer, Interim Principal Financial Officer* | January 27, 2026 |
| /s/ Oliver Dolan<br>Oliver Dolan | Senior Vice President, Finance<br>*Principal Accounting Officer*<br>| January 27, 2026 |
| /s/ Ali Behbahani<br>Ali Behbahani | Director<br>| January 27, 2026 |
| /s/ Nessan Bermingham<br>Nessan Bermingham<br>| Director | January 27, 2026 |
| /s/ Jean-Francois Formela<br>Jean-Francois Formela<br>| Director | January 27, 2026 |
| /s/ Katharine Knobil<br>Katharine Knobil<br>| Director | January 27, 2026 |
| /s/ Rachel Meyers<br>Rachel Meyers<br>| Director | January 27, 2026 |
| /s/ Timothy Pearson<br>Timothy Pearson | Director | January 27, 2026 |

---

------

## Exhibit 5.1

**Exhibit 5.1** 

January 27, 2026

Korro Bio, Inc.

60 First Street, 2nd floor, Suite 250

Cambridge, Massachusetts 02141

Re: <u>Securities Being Registered under Registration Statement on Form S-8</u>

We have acted as your counsel in connection with your filing of a Registration Statement on Form S-8 (the "Registration Statement") pursuant to the Securities Act of 1933, as amended (the "Securities Act"), on or about the date hereof relating to an aggregate of 554,096 shares (the "Shares") of Common Stock, par value $0.001 per share ("Common Stock"), of Korro Bio, Inc., a Delaware corporation (the "Company"), that may be issued pursuant to the Korro Bio, Inc. 2023 Stock Option and Incentive Plan and the Korro Bio, Inc. 2023 Employee Stock Purchase Plan (collectively, the "Plans").

We have reviewed such documents and made such examination of law as we have deemed appropriate to give the opinion set forth below. We have relied, without independent verification, on certificates of public officials and, as to matters of fact material to the opinion set forth below, on certificates of officers of the Company.

For purposes of the opinion set forth below, we have assumed that, at the time Shares are issued, the total number of then unissued Shares, when added to the number of shares of Common Stock issued, subscribed for, or otherwise committed to be issued, does not exceed the number of shares of Common Stock authorized by the Company's certificate of incorporation.

The opinion set forth below is limited to the Delaware General Corporation Law.

Based on the foregoing, we are of the opinion that the Shares have been duly authorized and, when delivered against payment therefor in accordance with the terms of the Plans, will be validly issued, fully paid and nonassessable.

This opinion letter and the opinion it contains shall be interpreted in accordance with the Core Opinion Principles as published in 74 *Business Lawyer* 815 (Summer 2019).

We hereby consent to the inclusion of this opinion as Exhibit 5.1 to the Registration Statement. In giving our consent, we do not admit that we are in the category of persons whose consent is required under Section 7 of the Securities Act or the rules and regulations thereunder.

---

| |
|:---|
| Very truly yours, |
| /s/ Goodwin Procter LLP<br>GOODWIN PROCTER LLP |

---

------

## Exhibit 23.1

**Exhibit 23.1** 

**Consent of Independent Registered Public Accounting Firm** 

We consent to the incorporation by reference in the Registration Statement (Form S-8) pertaining to the 2023 Stock Option and Incentive Plan and 2023 Employee Stock Purchase Plan of Korro Bio, Inc. of our report dated March 18, 2025, with respect to the consolidated financial statements of Korro Bio, Inc. included in its Annual Report (Form 10-K) for the year ended December 31, 2024, filed with the Securities and Exchange Commission.

---

| |
|:---|
| /s/ Ernst & Young LLP |
| Boston, Massachusetts |
| January 27, 2026 |

---

------

## Ex-Filing

?xml version='1.0' encoding='ASCII'? EX-FILING FEES

**Exhibit 107**

**Calculation of** Filing Fee **Tables** 

<u>Form</u> S-8

(Form Type)

Korro Bio, Inc.

(Exact name of Registrant as Specified in its Charter)

<u>Table 1: Newly Registered Securities</u> 

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| &nbsp;&nbsp;&nbsp;Security Type | Security<br>Class<br>Title | Fee<br>Calculation<br>Rule | Amount<br>Registered(1) | Proposed<br>Maximum<br>Offering<br>Price Per<br>Unit | Maximum<br>Aggregate<br>Offering<br>Price | Fee<br>Rate | Amount of<br>Registration<br>Fee |
| &nbsp;&nbsp;&nbsp;Equity | Common Stock, $0.001 par value per share | 457(h) | 470865(2) | $8.99(3) | $4233076.35 | $0.00013810 | $584.59 |
| &nbsp;&nbsp;&nbsp;Equity | Common Stock, $0.001 par value per share | 457(h) | 83231(4) | $7.64(5) | $635884.84 | $0.00013810 | $87.82 |
| &nbsp;&nbsp;&nbsp;Total Offering Amounts | &nbsp;&nbsp;&nbsp;Total Offering Amounts | &nbsp;&nbsp;&nbsp;Total Offering Amounts | &nbsp;&nbsp;&nbsp;Total Offering Amounts |  | $4868961.19 |  | $672.41 |
| &nbsp;&nbsp;&nbsp;Total Fee Offsets | &nbsp;&nbsp;&nbsp;Total Fee Offsets | &nbsp;&nbsp;&nbsp;Total Fee Offsets | &nbsp;&nbsp;&nbsp;Total Fee Offsets |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Net Fee Due | &nbsp;&nbsp;&nbsp;Net Fee Due | &nbsp;&nbsp;&nbsp;Net Fee Due | &nbsp;&nbsp;&nbsp;Net Fee Due |  |  |  | $672.41 |

---

(1) Pursuant to Rule 416 under the Securities Act of 1933, as amended (the "Securities Act"), this Registration Statement on Form S-8 ("Registration Statement") shall also cover any additional shares of common stock, $0.001 par value per share (the "Common Stock") of Korro Bio, Inc. (the "Registrant") that become issuable under the Korro Bio, Inc. 2023 Stock Option and Incentive Plan (the "2023 Plan") and the Korro Bio, Inc. 2023 Employee Stock Purchase Plan (the "2023 ESPP") by reason of any stock dividend, stock split, recapitalization or any other similar transactions.

(2) Represents an automatic increase of 470,865 shares of Common Stock available for issuance under the 2023 Plan effective as of January 1, 2026. Shares available for issuance under the 2023 Plan were previously registered on registration statements on Form S-8 (File No. 333-275354, File No. 333-278245 and File No. 333-285873) filed with the Securities and Exchange Commission on November 6, 2023, March 26, 2024 and March 18, 2025, respectively.

(3) Estimated solely for the purpose of calculating the registration fee pursuant to Rule 457 of the Securities Act, and based on $8.99, the average of the high and low sale prices of the Common Stock as reported on Nasdaq on January 21, 2026 (such date being within five business days of the date that this Registration Statement was filed with the Commission).

(4) Represents an automatic increase of 83,231 shares of Common Stock available for issuance under the 2023 ESPP, effective as of January 1, 2026. Shares available for issuance under the 2023 ESPP were previously registered on a registration statement on Form S-8 (File No. 333-275354, File No. 333-278245 and File No. 333-285873) filed with the Securities and Exchange Commission on November 6, 2023, March 26, 2024 and March 18, 2025, respectively.

(5) Estimated solely for the purpose of calculating the registration fee pursuant to Rule 457 of the Securities Act, and based on 85% (the percentage of the price per share applicable to purchases under the 2023 ESPP) of $7.64, the average of the high and low sale prices of the Common Stock as reported on Nasdaq on January 21, 2026 (such date being within five business days of the date that this Registration Statement was filed with the Commission.

------